Background: High-grade neuroendocrine tumours (HGNTs) of the lung manifest a wide spectrum of clinical behaviour, but no method for predicting their outcome has been established.
introduction Neuroendocrine (NE) tumours comprise 20%-25% of all human lung malignancies and are classified into four histological subtypes: typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) [1, 2] . TC and AC are tumours with low-to intermediate-grade malignancy, whereas LCNEC and SCLC are highly aggressive and collectively referred to as high-grade neuroendocrine tumours (HGNTs) [3] [4] [5] [6] .
LCNEC appeared in the World Health Organization (WHO) Histological Typing of Lung and Pleural Tumours (third version, 1999) as a new entity of large cell carcinoma [2] . LCNEC shows aggressive behaviour distinct from other nonsmall cell lung cancers (NSCLCs) [7] , and thus its accurate discrimination is essential for the management of lung cancer patients. TC, AC and SCLC can be readily diagnosed on the basis of their histological characteristics, but the diagnosis of LCNEC is more complicated. The morphological features of NE differentiation are often inconspicuous, especially in small biopsy or cytology specimens [2] .
Three NE markers are used routinely for immunohistochemical assessment of NE differentiation: neural cell adhesion molecule (CD56), chromogranin A (CGA) and synaptophysin (SYN). However, a significant proportion of LCNECs are negative for any of these NE markers [7] , and more problematically, some non-NE lung cancers also show equivocal immunoreactivity for these markers [7, 8] . Therefore, it is necessary to develop a new diagnostic biomarker with higher specificity.
Actinin-4 is an actin-binding protein that we originally identified as being associated with enhanced cell motility and cancer invasion [9] . The actinin-4 (ACTN4) gene has a unique structure (supplementary Figure S1 , available at Annals of Oncology online), possessing two exons 8 (8 and 8⍰) of the same size, the mutually exclusive use of which leads to the production of two kinds of mRNA. The transcript obtained with exon 8 is expressed ubiquitously (namely, the ubiquitous form or ACTN4-Ub), whereas the expression of the variant transcript obtained with exon 8⍰ (the variant form or ACTN4-Va) is undetectable in normal tissues except for testis and brain [10, 11] . We previously found that the variant transcript is frequently expressed in SCLCs and that the gene product can be categorized as a so-called cancer-testis antigen [10] . However, the clinical significance of variant actinin-4 has remained undetermined due to lack of a specific probe.
The alternatively spliced actinin-4 variant transcript is predicted to encode a polypeptide differing in only three amino acids. To produce an antibody that can detect this small difference, we used the GANP (germinal centre-associated nuclear protein) technology [12] . GANP transgenic mice generate a highly diverse spectrum of antibodies and have been used to produce high-affinity antibodies against various difficult antigens, such as those with small protein modifications [13] . Here, we report the establishment of a highly specific antibody recognizing variant actinin-4 protein and the potential utility of variant actinin-4 not only as a new diagnostic biomarker but also as a highly potent prognostic biomarker for HGNTs.
materials and methods

cell lines and sequencing
Total RNA was extracted from 91 human cancer cell lines (31 lung cancers, 23 colorectal cancers, 7 stomach cancers, 5 hepatocellular carcinomas, 6 pancreatic cancers, 4 choriocarcinomas, 4 ovary cancers, 4 oral cancers, 3 prostate cancers, 2 breast cancers, 1 bladder cancer and 1 cervical cancer) using TRIzol reagent (Life Technologies, Grand Island, NY) (supplementary Table S1 , available at Annals of Oncology online).
First-strand complementary DNA (cDNA) was synthesized in the presence of random primers using the high-capacity cDNA reverse transcription kit (Life Technologies) in accordance with the manufacturer's instructions. The entire coding region of ACTN4 was amplified and sequenced using the BigDye Terminator v3.1 Cycle Sequencing Ready Reaction Kit (Life Technologies).
production of monoclonal antibodies GANP transgenic mice were immunized with a synthetic peptide (NQSYQYGPSSAGNGAG) to produce a monoclonal antibody (namely 13G9) reactive with all the known forms (ubiquitous and variant) of actinin-4. Another monoclonal antibody specific to variant actinin-4 (namely 15H2) was raised against a synthetic peptide (DIVGTLRPDEKAIMTYVSC). The reactivity and titre of antibodies against the various peptides were assessed by the antibody capture assay as described previously [13] .
western blot analysis
The PCR-amplified fragments encoding the ubiquitous and variant forms of actinin-4 (amino acids 28-911) were cloned into the EcoRI and KpnI sites of the pEGFP-C1 vector (Takara Bio, Otsu, Japan) to express the ubiquitous and variant actinin-4 proteins fused with green fluorescent protein (GFP) at the N-termini (namely pEGFP-ACTN4-Ub and pEGFP-ACTN4-Va, respectively). The nucleotide sequences of all the PCRamplified fragments were verified by sequencing. HEK293 cells (Health Science Research Resources Bank, Osaka, Japan) were transfected with each plasmid using Lipofectamine 2000 reagent (Life Technologies).
Western blotting was carried out following standard procedures, as described previously [14, 15] . Cells were extracted with lysis buffer [10 mmol/l HEPES ( pH 7.4), 150 mmol/l NaCl, 1 mmol/l EDTA, 1% Triton X-100, 1% NP40 and 1 mg/ml NaN 3 ] containing a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) on ice for 30 min. Ten micrograms of cell lysate were reduced, denatured at 70°C for 10 min and fractionated through NuPAGE 4%-12% Bis-Tris gel (Life Technologies). The fractionated proteins were then blotted onto PVDF membranes (Life Technologies). After incubation with the primary antibody at 4°C overnight, the blots were incubated with appropriate horseradish peroxidase-linked secondary antibodies and then detected by enhanced chemiluminescence (Western Lightning ECL Pro; Perkin-Elmer, Waltham, MA).
patients and tissue samples
Thirty-one tissue microarrays (TMAs) were constructed from formalinfixed paraffin-embedded tissue blocks of 609 primary lung tumours that had been surgically resected at the National Cancer Center (NCC) Hospital (Tokyo, Japan) from 1982 to 2010 using a tissue-arraying instrument (KIN-1; Azumaya, Tokyo, Japan). Based on the Pathology and genetics of Tumours of the Lung, Pleura, Thymus and Heart [IARC (International Agency for Research on Cancer) WHO Classification of Tumours] (2004) [16] , the 609 tumours were classified into carcinoid (51 cases), SCLC (70 cases), LCNEC (106 cases), adenocarcinoma (164 cases), squamous cell carcinoma (166 cases) and other NSCLCs (52 cases). To reduce sampling bias due to tissue heterogeneity, we took duplicate core samples measuring 2.0 mm in diameter from two different areas of every tumour.
The 176 patients with HGNTs included 143 men and 33 women with a mean age of 66 years (19-84 years). One hundred and sixty-nine (96%) patients had a history of habitual cigarette smoking. The follow-up periods ranged from 1 to 286 months (median follow-up, 46 months). Patients were staged postsurgically into IA (52 cases), IB (25 cases), IIA (33 cases), IIB (16 cases), IIIA (37 cases), IIIB (7 cases) and IV (6 cases) according to the International Union against Cancer (UICC) TNM classification of malignant tumours (7th edition, 2010) [17] .
This study was conducted with approval from the Institutional Review Board of the NCC.
immunohistochemistry TMA blocks were then cut into 4-mm thick sections and subjected to immunohistochemistry (IHC). Immunostaining of actinin-4 proteins was carried out using the Ventana DABMap detection kit and an automated slide stainer (Discovery XT, Ventana Medical Systems, Tucson, AZ) [18, 19] . Immunoreactivity was classified as positive when ≥10% of cancer cells showed cytoplasmic or membrane staining detectable at a magnification of ×40 [20, 21] .
Deparaffinized TMA slides were incubated with anti-CD56 mouse monoclonal (1B6, Novocastra, Newcastle upon Tyne, UK), anti-CGA rabbit polyclonal (Dako, Glostrup, Denmark) or anti-SYN mouse monoclonal (27G12, Nichirei Biosciences, Tokyo, Japan) antibody for 1 h at room temperature. Immunoreactivity was detected with the EnVision plus kit (Dako) using 3, 3⍰-diaminobenzidine as the chromogen. For diagnosis of LCNEC, positive staining for at least one of the three NE markers was stipulated.
The results of IHC were judged by two investigators (AM and KT) who were blinded to any clinicopathological information, and any discrepancy in judgement was discussed.
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Overall survival was measured as the period from surgery to the date of death or last follow-up. Progression-free survival was defined as the length of time from surgery to the first detection of new lesions or death. Overall and progression-free survival was estimated by the Kaplan-Meier method using the StatFlex statistical software package (version 5.0, Artiteck, Osaka, Japan). Differences between the survival curves were assessed with the logrank test. Univariate and multivariate analyses were carried out using the Cox regression model. Other statistical tests were carried out using tools available in the R statistical package (version 2.12.0; http://www.r-project. org/). Differences were considered to be statistically significant at P < 0.05. results expression of the ACTN4 splice variant in cancer cell lines
We sequenced the entire coding region of the ACTN4 transcript in 91 cell lines derived from human cancers of various origins (supplementary Table S1 , available at Annals of Oncology online). No non-synonymous nucleotide substitution was detected except for those registered in the single nucleotide polymorphism database (http://www.ncbi.nlm.nih.gov/snp), indicating that somatic mutation of the ACTN4 gene is infrequent. However, we detected overlap of two sequences appearing in nucleotides 793-872 of the ACTN4 transcript (NM_004924.2) (supplementary Figure S2A , available at Annals of Oncology online) in 25% (23/91) of the cell lines. These two transcripts were separately cloned, and their nucleotide sequences were confirmed to be identical to the ubiquitous and variant transcripts of ACTN4 that we had described previously [10] (supplementary Figure S2B , available at Annals of Oncology online).
The ubiquitous form of the ACTN4 transcript (namely ACTN4-Ub) was expressed in all of the 91 human cancer cell lines examined, but the variant form (namely ACTN4-Va) was detected in 90% (18/20) of the SCLC cell lines examined (SBC-3, SBC-5, MS-1-L, Lu-135, Lu-143, STC-1, Lu-138, Lu-140, DMS153, DMS53, H1688, Wa-hT, H69AR, RERF-LCMS, Lu165, H69, Lu134-AH, Lu134-B, Lu-141 and Lu-139) and 25% (1/4) of the cell lines derived from pulmonary carcinoid tumour (NCI-H727, NCI-H835, UMC-11 and NCI-H720) (supplementary Table S1 , available at Annals of Oncology online). In addition, the variant ACTN4 mRNA was detected in 33% (1/3) of prostate cancers and 75% (3/4) of choriocarcinoma cell lines. However, none of the seven non-SCLC-derived cell lines examined (A549, PC9, LCD, LCKJ, LK-2, Lu-65 and Lu-99) expressed the variant transcript.
production of antibody specific to variant actinin-4 protein
Although there was a difference of only three amino acid residues between the ubiquitous and variant actinin-4 protein sequences deduced from their cDNA sequences (supplementary Figure S2C , available at Annals of Oncology online), we were able to produce a monoclonal antibody (15H2) that reacted specifically with a peptide for which the amino acid sequence was derived from the variant actinin-4 protein (DIVGTLRPDEKAIMTYVSC), but not with the corresponding sequence of the ubiquitous protein (DIVNTARPDEKAIMTYVSS) (underlining indicates the amino acids that differed) ( Figure 1A) .
To further confirm that the 15H2 monoclonal antibody reacted specifically with the variant form of actinin-4 protein, HEK 293 cells were transfected with a plasmid encoding the ubiquitous (pEGFP-ACTN4-Ub) or variant (pEGFP-ACTN4-Va) form of actinin-4. We found that the 15H2 antibody reacted only with a lysate prepared from HEK 293 cells transfected with pEGFP-ACTN4-Va, but not with those prepared from cells transfected with pEGFP-ACTN4-Ub or the parental pEGFP-C1 vector (ACTN4-Va, Figure 1B) . On the other hand, the monoclonal antibody 13G9 reacted with both the ubiquitous and variant actinin-4 proteins (pan-ACTN4, Figure 1B) . 
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The expression of endogenous variant actinin-4 was detected in all three SCLC cell lines examined (SBC-3, Lu-135 and Lu-165), but in none of the three non-SCLC cell lines (LCD, LK-2 and EBC-1) ( Figure 1C ), being consistent with the results of cDNA sequencing described above.
significance of variant actinin-4 expression in the diagnosis of HGNT
We next investigated immunohistochemically the expression of both actinin-4 proteins and classical NE markers (CGA, SYN and CD56) in 609 primary lung tumours. Representative results of immunohistochemical staining are shown in Figure 2 , and the positivity rates for each histological subtype are summarized in Table 1 CGA, SYN and CD56 were found to show variable expression in non-NE lung tumours (2%-11% of adenocarcinomas, 2%-14% of squamous cell carcinomas and 6%-17% of other NSCLCs). However, variant actinin-4 protein was expressed in only 0.8% (3/382) of non-NE NSCLCs. These results indicated that variant actinin-4 was highly specific to HGNTs.
prognostic significance of variant actinin-4 expression
There was no significant difference between patients with HGNTs that were positive (n = 96) and negative (n = 80) for variant actinin-4 protein expression with respect to gender, age, smoking status, histological subtype (LCNEC versus SCLC), pathological stage, tumour size or frequency of lymph node or distant metastasis (Table 2 ). However, the frequency of relapse after surgery was much higher in stage I to III HGNT cases that were positive for variant actinin-4 protein expression [67% (53/79)] than in cases that were negative [43% (39/91)] (P = 0.0020, Fisher's exact test) ( Table 2 ). The sites of first recurrence in patients with HGNTs that were positive for variant actinin-4 expression included the brain (16 cases), lymph nodes (16 cases), lung (9 cases), liver (6 cases), and bone (5 cases), but the site distribution did not differ significantly from that in negative cases.
The overall survival of patients with variant actinin-4-positive HGNT, SCLC and LCNEC was significantly worse than that of patients whose tumours were negative [P = 0.00021 (HGNT, Figure 3A) , 0.0283 (SCLC, supplementary Figure S3A , available at Annals of Oncology online) and 0.0022 (LCNEC, supplementary Figure S3B , available at Annals of Oncology online), log-rank test]. Furthermore, progression-free survival also differed significantly between patients whose tumours were positive and negative for variant actinin-4 expression [P = 0.0021 (HGNT, Figure 3B ), 0.018 (SCLC, supplementary Figure S3C , available at Annals of Oncology online) and 0.048 (LCNEC, supplementary Figure S3D , available at Annals of Oncology online), log-rank test]. The 5-year survival rates of patients with variant actinin-4-negative HGNT, SCLC and LCNEC were 62%, 62% and 62%, respectively, whereas those of 
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patients whose tumours were positive were 42%, 32% and 49%, respectively. The prognostic significance of variant actinin-4 protein expression was reproducibly observed in subgroup analyses of patients with stages I and II and stages III and IV HGNT (P = 0.0089 and P = 0.049, respectively) ( Figure 3C and D), whereas the expression of total actinin-4 proteins (detected by 13G9 monoclonal antibody) (supplementary Figure S4 , available at Annals of Oncology online) or the three conventional NE markers (CGA, SYN and CD56) (supplementary Figure S5 , available at Annals of Oncology online) did not show such prognostic significance. Univariate analysis with the Cox proportional hazards model (Table 3) revealed that lymph node metastasis (P = 0.000082) and immunoreactivity for the actinin-4 splice variant (P = 0.000467) were significantly correlated with the outcome of the 173 patients with HGNTs. Multivariate analysis indicated that the expression of the actinin-4 splice variant was the most significant independent predictor of unfavourable outcome (P = 0.00113; hazard ratio (HR), 2.15; 95% confidence interval (CI) 1.36-3.40) after the presence of lymph node metastasis (P = 0.00023; HR, 2.25; 95% CI 1.46-3.47). The variant actinin-4 protein expression was also a significant independent predictor of outcome for SCLC (supplementary Table S2 , available at Annals of Oncology online) (P = 0.050; HR, 2.16; 95% CI 1.00-4.68) and LCNEC (supplementary Table S3 , available at Annals of Oncology online) (P = 0.0038; HR, 2.37; 95% CI 1.32-4.26).
discussion
In this study, we first determined the distribution of expression of the alternatively spliced ACTN4 transcript in a large panel of human cancer cell lines derived from various tissues. We confirmed the frequent expression of ACTN-Va in SCLCs and the absence of its expression in NSCLCs. The variant transcript was also expressed frequently in choriocarcinoma, but its relationship with NE differentiation as well as its clinical significance remained undetermined. We then investigated the expression of the variant actinin-4 protein in a variety of histological subtypes of lung cancer using a newly established monoclonal antibody (Figure 1 ). We found that the expression pattern of the variant protein was apparently different from any of the conventional NE markers. CGA, SYN and CD56 were expressed in 76%-100% of pulmonary carcinoid tumours (Table 1) , whereas the variant actinin-4 was expressed in only 10% (5/51) of them. The expression of variant actinin-4, but not that of CGA, SYN or CD56, was significantly associated with an unfavourable post-surgical outcome in HGNT patients ( Figure 3 and supplementary Figure S5 , available at Annals of Oncology online). These results indicated that variant actinin-4 original articles Annals of Oncology is not a simple marker for NE differentiation, but seems to be associated with the malignant progression of NE tumours. We originally identified actinin-4 as an actin-bundling protein associated with enhanced cell motility and cancer invasion [9] . Actinin-4 directly regulates cell motility through remodelling of the actin cytoskeleton [9, 22] . Increased expression of actinin-4 protein is closely associated with a poor outcome in patients with breast cancer [9] , colorectal cancer [22] , pancreatic cancer [18] , ovarian cancer [19] and NSCLC [23] . However, the expression of total actinin-4 protein (i.e. the ubiquitous and variant actinin-4 proteins together) detected by the monoclonal antibody 13G9 was not significantly correlated with the outcome of HGNT patients (supplementary Figure S4 , available at Annals of Oncology online). The amino acid sequence encoded by exon 8 is crucial for the function of the ACTN4 gene. In fact, a germline missense mutation in exon 8 is responsible for a hereditary renal disease, familial focal segmental glomerulosclerosis [24] . The splice variant as well as mutated actinin-4 proteins have a higher affinity for actin polymers [10] . SCLC shows an abnormal actin cytoskeleton structure [10] . Existing experimental data as well as the current clinical observations suggest that variant actinin-4 very likely plays a functional role in the aggressive behaviour of NE lung tumours. Because of its limited expression in normal tissues, variant actinin-4 may also serve as a therapeutic target.
If a biomarker capable of defining a subset of HGNT patients whose prognosis is likely to be unfavourable were to be identified, allowing them to be selected for intense adjuvant chemotherapy, then their survival might be improved. Recently Klotho was newly characterized as a biomarker predictive of a favourable outcome in patients with LCNEC [25] and limiteddisease SCLC [26] , although the number of cases examined was relatively small. The expression of CD117 was also reported to show marginally significant correlation with recurrence of LCNEC (P = 0.046) [27] . It is expected that combination of these emerging prognostic biomarkers with variant actinin-4 would further improve the accuracy of HNGT prognostication. Future investigation to select and validate an optimal biomarker set is anticipated. Three patients with LCNEC, for whom no data regarding adjuvant therapy were available, were excluded from the analysis. HR, hazard ratio; CI, confidence interval; LCNEC, large cell neuroendocrine carcinoma; SCLC, small cell lung carcinoma.
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